Journal Article 1 Mention
Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood
Niklas Worm Andersson2025
Ingrid Bech SvalgaardStine Skovbo Hoffmann
Top 25% · 75th percentile
30 citations · Plant Science

TLDR

Getting vaccines that contain aluminum in early childhood does not increase the risk of developing long-term diseases like allergies, autoimmune problems, or learning disorders.

Summary

1 Study Aim

The study set out to determine whether receiving vaccines containing aluminum (a common vaccine ingredient that helps boost immune response) during the first two years of life is linked to a higher risk of developing chronic diseases. These diseases include autoimmune disorders (where the immune system attacks the body), atopic or allergic conditions (such as asthma or eczema), and neurodevelopmental disorders (like autism spectrum disorder and attention deficit-hyperactivity disorder). The researchers wanted to see if aluminum in vaccines causes long-term health problems in children.

2 Study Design

The authors conducted a cohort study using data from Danish national registries. They included 1,224,176 children born in Denmark between 1997 and 2018 who were alive and living in the country at age two. The study tracked how much aluminum each child received from vaccines in their first two years. Researchers then looked for new cases of 50 different chronic diseases, including autoimmune, allergic, and neurodevelopmental disorders. They used statistical methods to adjust for other factors that could affect the results, such as differences in vaccine schedules over time. The study followed a large group of Danish children to see if more aluminum from vaccines led to more long-term illnesses.

3 Findings

The research demonstrates that there was no link between the amount of aluminum children received from vaccines in their first two years and the risk of developing any of the 50 chronic diseases studied. The adjusted hazard ratios for autoimmune, allergic, and neurodevelopmental disorders were all close to 1, meaning no increased risk was found. For most diseases, the results ruled out even moderate increases in risk, though very small risks for rare diseases could not be completely excluded. The authors note that they did not review individual medical records, which is a limitation. They conclude that aluminum-containing vaccines in early childhood do not appear to raise the risk of chronic autoimmune, allergic, or neurodevelopmental diseases. The study found no evidence that aluminum in vaccines causes long-term health problems in children.

Abstract

BACKGROUND: Aluminum is used as an adjuvant in nonlive vaccines administered in early childhood. Concerns persist about potential associations between vaccination with aluminum-adsorbed vaccines and increased risk for chronic autoimmunity, atopy or allergy, and neurodevelopmental disorders. Large-scale safety data remain limited. OBJECTIVE: To assess the association between cumulative aluminum exposure from early childhood vaccination and risk for autoimmune, atopic or allergic, and neurodevelopmental disorders. DESIGN: A cohort study linking nationwide registry data on childhood vaccinations, outcome diagnoses, and potential confounders, leveraging the variations in the aluminum content of childhood vaccines over time. SETTING: Denmark, 1997 to 2020. PARTICIPANTS: 1 224 176 children born in Denmark between 1997 and 2018 who were alive and residing in the country at age 2 years. INTERVENTION: Cumulative aluminum amount received (per 1-mg increase) through vaccination during the first 2 years of life. MEASUREMENTS: Incident events of 50 chronic disorders, including autoimmune (dermatologic, endocrinologic, hematologic, gastrointestinal, and rheumatic), atopic or allergic (asthma, atopic dermatitis, rhinoconjunctivitis, and allergy), and neurodevelopmental (autism spectrum disorder and attention deficit-hyperactivity disorder). RESULTS: Cumulative aluminum exposure from vaccination during the first 2 years of life was not associated with increased rates of any of the 50 disorders assessed. For groups of combined outcomes, adjusted hazard ratios per 1-mg increase in aluminum exposure were 0.98 (95% CI, 0.94 to 1.02) for any autoimmune disorder, 0.99 (CI, 0.98 to 1.01) for any atopic or allergic disorder, and 0.93 (CI, 0.90 to 0.97) for any neurodevelopmental disorder. For most individually analyzed outcomes, the upper bounds of the 95% CIs were incompatible with relative increases greater than 10% or 30%. LIMITATION: Individual medical records were not reviewed. CONCLUSION: This nationwide cohort study did not find evidence supporting an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders associated with early childhood exposure to aluminum-adsorbed vaccines. For most outcomes, the findings were inconsistent with moderate to large relative increases in risk, although small relative effects, particularly for some rarer disorders, could not be statistically excluded. PRIMARY FUNDING SOURCE: None.

Referenced In